Skip to notes
CJC-1295 Visit Notes

I keep CJC-1295 study doses out of a personal plan

A number in a paper can look like the answer to a dosage search. I'd keep the rest of the sentence with it: who received it, which preparation they used and what the researchers were testing.

CJC-1295 has no FDA-approved drug label. There's no approved schedule here to turn into a few easy steps. This page explains the study context and leaves the personal decision with a clinician.

A prescription is only one part of the access question. FDA's 2024 review found no official ingredient quality standard for CJC-1295 and no approved drug containing it. It also isn't on the 503A bulks list used by ordinary pharmacies. A clinician's review doesn't replace those ingredient requirements.

A baker brushes flour from an enamel counter toward a red cloth, with dough and a plain bowl behind.
The small work of clearing a little space.

What researchers used

FDA's account of Teichman and colleagues' studies describes healthy adults receiving CJC-1295 doses ranging from 30 to 250 micrograms per kilogram. The research appeared to use the DAC form, but the exact salt wasn't specified. Those are amounts used in that research, not a suggested range for readers.

The published paper examined single and repeated injections under the skin and followed hormone responses. It didn't establish a treatment schedule for sleep, recovery or aging. Copying the amount without that context makes the research look like instructions it never supplied.

DAC is the added part that binds to albumin, a protein in blood, and helps the peptide stay in circulation longer. FDA's review found no human studies of the forms without DAC. The study range can't be carried over to those preparations.

A timing figure doesn't finish the calculation

The half-life page explains how researchers measured the time it took for the peptide's blood level to fall by half. That result doesn't tell us when a person would benefit or when another amount would be appropriate.

A longer duration isn't automatically better, either. FDA's clinical review describes faster heart rate and reactions involving widening blood vessels, including flushing and low blood pressure. It raises immune concerns and leaves long-term safety unresolved.

I'd want those questions kept beside any discussion of amounts. Body weight alone can't make missing evidence appear. A neat table would make this look settled when it isn't.

Three notes for the conversation

First, I'd bring the full preparation name and the claim that led me to it. The preparation notes explain why “with DAC” and “without DAC” need separate reading.

Second, I'd describe the original concern in everyday words. “I keep waking up” gives the conversation a different starting point from “I want a higher hormone level.” How long it's been happening belongs there too.

Third, I'd add current medicines, relevant health history and past reactions. Then I'd leave room to discuss other explanations and options. A clinician may recommend more assessment, another approach or no prescription; I want the notes to leave all of those answers possible.